Outcomes of subsequent anti-lymphoma therapies in patients (pts) with large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) or standard of care (SOC) in the second-line (2L) ZUMA-7 study Meeting Abstract
| Authors: | Ghobadi, A.; Munoz, J.; Westin, J.; Locke, F. L.; Miklos, D. B.; Rapoport, A. P.; Perales, M. A.; Reagan, P. M.; McGuirk, J. P.; Jacobson, C. A.; Kersten, M. J.; Avivi, I.; Peng, A.; Schupp, M.; To, C.; Oluwole, O. O. |
| Abstract Title: | Outcomes of subsequent anti-lymphoma therapies in patients (pts) with large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) or standard of care (SOC) in the second-line (2L) ZUMA-7 study |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 1595 |
| End Page: | 1597 |
| Language: | English |
| ACCESSION: | WOS:000893223201245 |
| DOI: | 10.1182/blood-2022-158303 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
